title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,BGNE,0.026343,Neutral,0.037824
"SAP's Q2 Earnings Decline Y/Y, Revenues Up on Cloud Strength",20220721T153900,https://www.zacks.com/stock/news/1955922/saps-q2-earnings-decline-yy-revenues-up-on-cloud-strength,BGNE,0.032078,Neutral,0.111421
Stocks That Hit 52-Week Lows On Tuesday,20220524T161351,https://www.benzinga.com/markets/options/22/05/27375519/52-weeks-high-and-low-article,BGNE,0.010175,Neutral,0.003559
"Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket - Akanda  ( NASDAQ:AKAN ) , Aspen Aerogels  ( NYSE:ASPN ) ",20221130T124216,https://www.benzinga.com/news/22/11/29903371/why-horizon-therapeutics-shares-are-trading-higher-by-over-30-here-are-32-stocks-moving-premarket,BGNE,0.110462,Neutral,0.0
"Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session - Beauty Health  ( NASDAQ:SKIN ) ",20240313T101613,https://www.benzinga.com/news/24/03/37649482/beauty-health-posts-upbeat-sales-joins-siga-technologies-maxcyte-and-other-big-stocks-moving-higher,BGNE,0.24289,Somewhat-Bullish,0.346732
Stocks That Hit 52-Week Lows On Thursday,20220310T165722,https://www.benzinga.com/news/22/03/26083670/stocks-that-hit-52-week-lows-on-thursday,BGNE,0.014015,Neutral,-0.007427
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates,20230228T210100,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-updates-301758465.html,BGNE,0.042953,Neutral,0.022323
"Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket - Bone Biologics  ( NASDAQ:BBLG ) , Applied UV  ( NASDAQ:AUVI ) ",20230615T120517,https://www.benzinga.com/news/23/06/32871563/why-microvision-shares-are-trading-higher-by-28-here-are-20-stocks-moving-premarket,BGNE,0.222157,Neutral,-0.029557
99 Biggest Movers From Yesterday,20220512T082956,https://www.benzinga.com/news/22/05/27156577/99-biggest-movers-from-yesterday,BGNE,0.063655,Neutral,-0.017103
Novartis  ( NVS )  Anti-PD-1 Drug Validated by EMA for Lung Cancer,20220407T160500,https://www.zacks.com/stock/news/1894957/novartis-nvs-anti-pd-1-drug-validated-by-ema-for-lung-cancer,BGNE,0.245278,Neutral,0.023742
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,BGNE,0.040795,Neutral,0.032589
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,BGNE,0.018757,Neutral,0.026387
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",20230918T210100,https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,BGNE,0.069361,Neutral,0.052186
"PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday - Acadia Healthcare Co  ( NASDAQ:ACHC ) , Boeing  ( NYSE:BA ) ",20221212T133932,https://www.benzinga.com/news/22/12/30040797/paypal-to-rally-around-47-here-are-10-other-price-target-changes-for-monday,BGNE,0.272788,Somewhat-Bullish,0.277959
"The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China",20220311T125204,https://www.benzinga.com/general/biotech/22/03/26098907/the-daily-biotech-pulse-valneva-gains-on-covid-shot-regulatory-update-lucira-health-and-clearside,BGNE,0.146425,Neutral,-0.004485
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,20230821T210100,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,BGNE,0.024347,Neutral,-0.03954
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer,20241121T170800,https://www.zacks.com/stock/news/2373587/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer,BGNE,0.073321,Neutral,0.05335
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",20230906T210100,https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,BGNE,0.022494,Neutral,0.023078
Zymeworks Appoints New Director - Zymeworks  ( NASDAQ:ZYME ) ,20230629T200500,https://www.benzinga.com/pressreleases/23/06/g33066902/zymeworks-appoints-new-director,BGNE,0.096671,Neutral,0.071177
"The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures",20220714T130111,https://www.benzinga.com/general/biotech/22/07/28062629/the-daily-biotech-pulse-much-awaited-fda-nod-for-novavaxs-covid-19-shot-dsmb-suggests-contrafect-,BGNE,0.114137,Neutral,0.0
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",20231009T210100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,BGNE,0.018173,Neutral,0.026267
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20240711T213100,https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html,BGNE,0.024904,Neutral,0.028471
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial,20230717T133700,https://www.globenewswire.com/news-release/2023/07/17/2705723/0/en/Immix-Biopharma-Reports-2nd-Positive-Interim-Clinical-Trial-Data-Readout-in-Relapsed-Refractory-Metastatic-Colorectal-Cancer-in-Ongoing-Phase-1b-2a-IMX-110-IMMINENT-01-Clinical-Tri.html,BGNE,0.053689,Neutral,0.019013
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis - Immix Biopharma  ( NASDAQ:IMMX ) ,20230522T154819,https://www.benzinga.com/general/biotech/23/05/32508031/immix-biopharmas-subsidiary-says-investigational-car-t-therapy-shows-100-response-rate-in-amyloid,BGNE,0.279015,Somewhat-Bullish,0.236262
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy  ( ASGCT ) ,20230504T163000,https://www.globenewswire.com/news-release/2023/05/04/2661902/0/en/Immix-Biopharma-Announces-Late-Breaking-NXC-201-Clinical-Data-Abstract-Accepted-for-Oral-Presentation-at-the-26th-Annual-Meeting-of-The-American-Society-of-Gene-and-Cell-Therapy-AS.html,BGNE,0.028558,Neutral,0.027725
What's Going On With Immix Biopharma  ( IMMX )  Stock Today - Immix Biopharma  ( NASDAQ:IMMX ) ,20230503T184211,https://www.benzinga.com/general/biotech/23/05/32191738/whats-going-on-with-immix-biopharma-stock-today,BGNE,0.334008,Somewhat-Bullish,0.297389
"Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain  ( AL )  Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris",20230426T213000,https://www.globenewswire.com/news-release/2023/04/26/2655734/0/en/Nexcella-an-Immix-Biopharma-subsidiary-Announces-Positive-58-Patient-NXC-201-Clinical-Data-100-Overall-Response-Rate-in-Light-Chain-AL-Amyloidosis-92-Overall-Response-Rate-in-Multi.html,BGNE,0.017835,Neutral,0.026214
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial,20230113T130000,https://www.globenewswire.com/news-release/2023/01/13/2588550/0/en/Immix-Biopharma-Doses-Additional-Patients-in-Ongoing-Phase-1b-2a-IMX-110-Monotherapy-Clinical-Trial.html,BGNE,0.048133,Neutral,0.14823
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial,20221220T130000,https://www.globenewswire.com/news-release/2022/12/20/2577016/0/en/Immix-Biopharma-Announces-16th-Patient-Dosing-in-Ongoing-Phase-1b-2a-IMX-110-Monotherapy-Clinical-Trial.html,BGNE,0.04823,Somewhat-Bullish,0.161834
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors,20221219T130000,https://www.globenewswire.com/news-release/2022/12/19/2576254/0/en/ImmixBio-Ships-Tislelizumab-for-Patient-Dosing-in-its-Combination-Clinical-Trial-with-IMX-110-in-Advanced-Solid-Tumors.html,BGNE,0.143987,Neutral,0.097609
Penny Stocks To Buy? 4 To Watch Before Next Week,20221215T184059,https://pennystocks.com/featured/2022/12/15/penny-stocks-to-buy-4-to-watch-before-next-week/,BGNE,0.041251,Neutral,0.013835
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial,20221213T130000,https://www.globenewswire.com/news-release/2022/12/13/2572651/0/en/Immix-Biopharma-Announces-Patient-Dosing-in-Ongoing-Phase-1b-2a-IMX-110-Monotherapy-Clinical-Trial.html,BGNE,0.136113,Neutral,0.013519
Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26 - Immix Biopharma  ( NASDAQ:IMMX ) ,20221025T120032,https://www.benzinga.com/pressreleases/22/10/g29394221/immix-biopharma-to-present-milestones-achieved-to-enable-kick-off-of-2-imx-110-clinical-trials-at-,BGNE,0.047844,Neutral,0.118825
Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26,20221025T120000,https://www.globenewswire.com/news-release/2022/10/25/2540814/0/en/Immix-Biopharma-to-Present-Milestones-Achieved-to-Enable-Kick-Off-of-2-IMX-110-Clinical-Trials-at-the-2022-ThinkEquity-Conference-on-October-26.html,BGNE,0.050572,Neutral,0.119319
 ( IMMX )  - ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials,20220907T160534,https://www.benzinga.com/pressreleases/22/09/g28780904/immixbio-completes-gmp-manufacturing-of-scaled-up-batch-of-imx-110-for-clinical-trials,BGNE,0.148426,Neutral,0.110953
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials,20220907T160500,https://www.globenewswire.com/news-release/2022/09/07/2511863/0/en/ImmixBio-Completes-GMP-Manufacturing-of-Scaled-Up-Batch-of-IMX-110-for-Clinical-Trials.html,BGNE,0.106778,Neutral,0.086371
"Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Oxford Industries  ( NYSE:OXM ) ",20240912T120218,https://www.benzinga.com/news/24/09/40830584/oxford-industries-reports-weak-results-joins-viper-energy-and-other-big-stocks-moving-lower-in-thurs,BGNE,0.249106,Neutral,-0.022283
